274 related articles for article (PubMed ID: 26914924)
21. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
[TBL] [Abstract][Full Text] [Related]
22. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
[TBL] [Abstract][Full Text] [Related]
23. First
Starke L; Millward JM; Prinz C; Sherazi F; Waiczies H; Lippert C; Nazaré M; Paul F; Niendorf T; Waiczies S
Theranostics; 2023; 13(4):1217-1234. PubMed ID: 36923535
[TBL] [Abstract][Full Text] [Related]
24. Siponimod Chips Away at Progressive MS.
Longbrake EE; Hafler DA
Cell; 2019 Dec; 179(7):1440. PubMed ID: 31951523
[TBL] [Abstract][Full Text] [Related]
25. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
[TBL] [Abstract][Full Text] [Related]
26. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.
Wu Q; Mills EA; Wang Q; Dowling CA; Fisher C; Kirch B; Lundy SK; Fox DA; Mao-Draayer Y;
JCI Insight; 2020 Feb; 5(3):. PubMed ID: 31935197
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory effects of siponimod on astrocytes.
Ogasawara A; Takeuchi H; Komiya H; Ogawa Y; Nishimura K; Kubota S; Hashiguchi S; Takahashi K; Kunii M; Tanaka K; Tada M; Doi H; Tanaka F
Neurosci Res; 2022 Nov; 184():38-46. PubMed ID: 35940437
[TBL] [Abstract][Full Text] [Related]
28. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.
Song Y; Lao Y; Liang F; Li J; Jia B; Wang Z; Hui X; Lu Z; Zhou B; Luo W; Song B
Medicine (Baltimore); 2019 Aug; 98(34):e15415. PubMed ID: 31441835
[TBL] [Abstract][Full Text] [Related]
30. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
[TBL] [Abstract][Full Text] [Related]
31. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Selmaj K; Li DK; Hartung HP; Hemmer B; Kappos L; Freedman MS; Stüve O; Rieckmann P; Montalban X; Ziemssen T; Auberson LZ; Pohlmann H; Mercier F; Dahlke F; Wallström E
Lancet Neurol; 2013 Aug; 12(8):756-67. PubMed ID: 23764350
[TBL] [Abstract][Full Text] [Related]
32. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
33. S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
Pelz A; Schaffert H; Diallo R; Hiepe F; Meisel A; Kohler S
Eur J Immunol; 2018 Mar; 48(3):498-508. PubMed ID: 29205338
[TBL] [Abstract][Full Text] [Related]
34. Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human.
Pognan F; Mahl JA; Papoutsi M; Ledieu D; Raccuglia M; Theil D; Voytek SB; Devine PJ; Kubek-Luck K; Claudio N; Cordier A; Heier A; Kolly C; Hartmann A; Chibout SD; Bouchard P; Trendelenburg C
Arch Toxicol; 2018 May; 92(5):1877-1891. PubMed ID: 29556671
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
[TBL] [Abstract][Full Text] [Related]
36. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA.
Ziemssen T; Hoffmann O; Klotz L; Schreiber H; Weber MS; Rauser B
JMIR Res Protoc; 2020 Jul; 9(7):e19598. PubMed ID: 32499214
[TBL] [Abstract][Full Text] [Related]
37. Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up.
Ludwig R; Malla B; Höhrhan M; Infante-Duarte C; Anderhalten L
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203434
[TBL] [Abstract][Full Text] [Related]
38. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
Front Immunol; 2021; 12():795574. PubMed ID: 34950154
[TBL] [Abstract][Full Text] [Related]
39. Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series.
Abbadessa G; Maida E; Miele G; Bile F; Lavorgna L; Bonavita S
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294354
[TBL] [Abstract][Full Text] [Related]
40. Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
Gilmartin CG; Hoyle N; Garjani A; Dixon T; Jos H; Paling D; Brownlee W; Tench C; Evangelou N
Mult Scler; 2024 Apr; 30(4-5):600-604. PubMed ID: 38323423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
